Insider Buying: Dyne Therapeutics (NASDAQ:DYN) Director Purchases 2,000 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The stock was acquired at an average cost of $16.94 per share, with a total value of $33,880.00. Following the completion of the acquisition, the director directly owned 24,500 shares in the company, valued at approximately $415,030. This represents a 8.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Dyne Therapeutics Stock Performance

DYN stock traded up $1.11 on Tuesday, reaching $17.92. The company’s stock had a trading volume of 1,701,207 shares, compared to its average volume of 1,965,884. The company has a market capitalization of $2.96 billion, a P/E ratio of -5.57 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The firm has a fifty day moving average of $18.24 and a two-hundred day moving average of $18.24.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company earned ($1.05) earnings per share. As a group, analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Creative Planning increased its position in Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after buying an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics during the first quarter worth $26,000. Caxton Associates LLP increased its position in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Dyne Therapeutics by 9.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,937 shares of the company’s stock worth $315,000 after buying an additional 2,108 shares during the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.